Drug Discovery 2021 After the Storm: Re-connect, Re-invent, Re-imagine
WuXi AppTec

Where: B3
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,800 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
Tel: +1 (888) 794-0077
Address: 5 New Street Square
London
Website: http://www.wuxiapptec.com/
Email:

Presentations at Drug Discovery 2021 After the Storm: Re-connect, Re-invent, Re-imagine

Staff Attending

Ambreen Anwer
WuXi AppTec
Shaymas Hussain
WuXi AppTec
Dr David Madge
Vice President, Discovery Services
WuXi AppTec